RU2011102743A - Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения - Google Patents

Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения Download PDF

Info

Publication number
RU2011102743A
RU2011102743A RU2011102743/15A RU2011102743A RU2011102743A RU 2011102743 A RU2011102743 A RU 2011102743A RU 2011102743/15 A RU2011102743/15 A RU 2011102743/15A RU 2011102743 A RU2011102743 A RU 2011102743A RU 2011102743 A RU2011102743 A RU 2011102743A
Authority
RU
Russia
Prior art keywords
determinants
subject
tumor
sample
level
Prior art date
Application number
RU2011102743/15A
Other languages
English (en)
Russian (ru)
Inventor
Линда ЧИН (US)
Линда ЧИН
Кеннет Л. СКОТТ (US)
Кеннет Л. СКОТТ
Папиа ГХОШ (US)
Папиа ГХОШ
Original Assignee
Дана-Фарбер Кэнсер Инститьют, Инк. (Us)
Дана-Фарбер Кэнсер Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дана-Фарбер Кэнсер Инститьют, Инк. (Us), Дана-Фарбер Кэнсер Инститьют, Инк. filed Critical Дана-Фарбер Кэнсер Инститьют, Инк. (Us)
Publication of RU2011102743A publication Critical patent/RU2011102743A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011102743/15A 2008-06-26 2009-06-26 Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения RU2011102743A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
US61/075,933 2008-06-26

Publications (1)

Publication Number Publication Date
RU2011102743A true RU2011102743A (ru) 2012-08-10

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011102743/15A RU2011102743A (ru) 2008-06-26 2009-06-26 Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения

Country Status (14)

Country Link
US (1) US20110182881A1 (https=)
EP (1) EP2307886A2 (https=)
JP (1) JP2011526693A (https=)
KR (1) KR20110036056A (https=)
CN (1) CN102132160A (https=)
AU (1) AU2009262022A1 (https=)
BR (1) BRPI0914734A2 (https=)
CA (1) CA2728674A1 (https=)
IL (1) IL210245A0 (https=)
MX (1) MX2010014280A (https=)
NZ (1) NZ590385A (https=)
RU (1) RU2011102743A (https=)
WO (1) WO2009158620A2 (https=)
ZA (1) ZA201100225B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
RU2012157998A (ru) 2010-06-01 2014-07-20 Тодос Медикал Лтд. Диагностика рака
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8880457B2 (en) * 2010-11-05 2014-11-04 Allegheny-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
WO2012153326A1 (en) 2011-05-11 2012-11-15 Todos Medical Ltd. Diagnosis of cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
CN104684398A (zh) 2012-08-31 2015-06-03 索隆-基特林癌症研究协会 粒子、方法以及其用途
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP6465811B2 (ja) 2012-12-19 2019-02-06 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 多様式の粒子、方法およびその使用
EP2958481A4 (en) 2013-02-20 2017-03-08 Sloan-Kettering Institute for Cancer Research Wide field raman imaging apparatus and associated methods
CA2904283A1 (en) 2013-03-14 2014-10-02 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma
ES2877332T3 (es) 2013-05-28 2021-11-16 Todos Medical Ltd Un método para indicar la presencia de tumores benignos mediante el uso de una muestra de células mononucleares de sangre periférica (PBMC)
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
AU2015225867B2 (en) * 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016018896A1 (en) 2014-07-28 2016-02-04 Memorial Sloan Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
US11009467B2 (en) * 2015-02-17 2021-05-18 Siemens Healthcare Diagnostics Inc. Model-based methods and apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
WO2017004301A1 (en) 2015-07-01 2017-01-05 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
TWI725248B (zh) * 2016-10-28 2021-04-21 茂英基因科技股份有限公司 辨識轉移性腫瘤的原發位置之方法及系統
TWI676688B (zh) * 2017-07-17 2019-11-11 茂英基因科技股份有限公司 辨識細胞種類型之方法及系統
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
EP4405507A4 (en) * 2021-09-20 2025-11-05 Droplet Biosciences Inc METHODS FOR DISEASE ASSESSMENT USING A DRAINAGE FLUID
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) * 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
EP2135960A1 (en) * 2001-09-19 2009-12-23 Intergenetics Incorporated Genetic analysis for stratification of cancer risk by determining the allelic profile of the VDR-ApaI and CYP11B2 genes
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
WO2005108621A1 (en) * 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
WO2007059313A1 (en) * 2005-11-16 2007-05-24 Children's Medical Center Corporation Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090069196A1 (en) * 2006-03-22 2009-03-12 Mathias Gehrmann Prediction of Breast Cancer Response to Chemotherapy
PT2062049E (pt) * 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
WO2008082730A2 (en) * 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CA2668831A1 (en) * 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
CA2680692A1 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
AU2008316319A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms
AU2009213689B2 (en) * 2008-02-14 2014-11-20 Decode Genetics Ehf. Susceptibility variants for lung cancer
WO2009124251A1 (en) * 2008-04-03 2009-10-08 Sloan-Kettering Institute For Cancer Research Gene signatures for the prognosis of cancer
EP2288728A4 (en) * 2008-05-15 2011-11-02 Univ Southern California GENOTYP AND EXPRESSION ANALYSIS FOR USE IN PROGNOSIS AND THERAPY SELECTION
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.

Also Published As

Publication number Publication date
JP2011526693A (ja) 2011-10-13
AU2009262022A1 (en) 2009-12-30
IL210245A0 (en) 2011-03-31
KR20110036056A (ko) 2011-04-06
EP2307886A2 (en) 2011-04-13
MX2010014280A (es) 2011-05-23
NZ590385A (en) 2012-11-30
US20110182881A1 (en) 2011-07-28
CA2728674A1 (en) 2009-12-30
WO2009158620A3 (en) 2010-06-03
CN102132160A (zh) 2011-07-20
BRPI0914734A2 (pt) 2015-10-20
ZA201100225B (en) 2011-10-26
WO2009158620A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
RU2011102743A (ru) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
JP2011526693A5 (https=)
Zaha Significance of immunohistochemistry in breast cancer
Kim et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
Colleoni et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
Ito et al. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma
Davies et al. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer
RU2011105627A (ru) Отличительные признаки (рс)-детерминанты, связанные с раком предстательной железы, и способы их применения
JP2011528442A5 (https=)
KR20100072283A (ko) 환자의 유전자-베이스 알고리즘적 암 예후 및 임상적 결과
Guzzo et al. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance
Mastrosimini et al. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors
Hacking et al. Potential pitfalls in diagnostic digital image analysis: experience with Ki-67 and PHH3 in gastrointestinal neuroendocrine tumors
CN102472753B (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
Ji et al. Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer
Li et al. AGR2 diagnostic value in nasopharyngeal carcinoma prognosis
JP2008292424A (ja) 腫瘍の検出方法
Miyashita et al. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates
Zhao et al. Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline‑based neoadjuvant chemotherapy
Takuwa et al. Characteristic immunophenotype of solid subtype component in lung adenocarcinoma
Konstantinidou et al. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas
RU2383339C1 (ru) Способ прогнозирования эффективности неоадъювантной химиотерапии при местнораспространенном раке яичников
Tay et al. Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer
ES3056977T3 (en) Methods of classifying barrett's esophagus
Han ER, PR and HER2 testing in breast cancer

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120627